📣From lead to pre-candidate nomination in 18 months. Explore the STORM Therapeutics case study

Contact
  • Integrated Drug Discovery

    Integrated Drug Discovery

    Overview

    We deliver truly integrated drug discovery programs. Our co-located teams accelerate compounds from target ID to candidate.

  • Target Identification & Validation

    Target Identification & Validation

    It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.

  • Hit Identification

    Hit Identification

    Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.

  • Hit-to-Lead

    Hit-to-Lead

    High-quality hits with early proof of concept are de-risked and profiled, ready to accelerate your program towards lead optimization.

  • Lead Optimization

    Lead Optimization

    Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.

Featured Resources

  • Modalities

    Modalities

    Overview

    Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.

  • Small Molecules

    Small Molecules

    Expert small molecule discovery from target ID to scale-up, delivering candidates designed for success and market impact.

  • Peptides

    Peptides

    Transforming complex peptide concepts into next-generation therapies through integrated design, advanced analytics, and collaborative end-to-end discovery expertise.

  • Targeted protein degradation

    Targeted protein degradation

    Leveraging induced proximity and CHARMED technology to rapidly design, test, and optimize degraders for previously ‘undruggable’ targets.

  • ADCs

    ADCs

    Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.

  • Biologics

    Biologics

    Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.

Featured Resources

  • Therapeutic Areas

    Therapeutic Areas

    Overview

    Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.

  • Oncology and Immuno-Oncology

    Oncology and Immuno-Oncology

    Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.

  • Inflammation and Immunology

    Inflammation and Immunology

    Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.

  • Neuroscience

    Neuroscience

    Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.

  • Metabolic Diseases

    Metabolic Diseases

    Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.

Featured Resources

  • CellCentric Lead Optimisation Campaign - CCS1477

    CellCentric Lead Optimisation Campaign - CCS1477

    Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.

    Case study
  • About Sygnature

    About Sygnature

    At Sygnature Discovery, we deliver world-leading drug discovery solutions to accelerate your compound from idea to clinic.

  • Meet our Team

    Meet our Team

    Our leadership team brings diverse experience and insight, driving collaboration and innovation across drug discovery.

  • Careers

    Careers

    Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.

Search Results

Search across news, resources and pages to quickly find relevant content on our site.

Loading…
Technical Notes
Plasma Protein Binding
About the Assay Sygnature Discovery’s Plasma Protein Binding (PPB) assay evaluates the extent to which…
Technical Notes
Blood Plasma Partitioning
About the Assay Sygnature Discovery’s Blood Plasma Partitioning (BPP) assay quantifies how test compounds distribute…
Technical Notes
CYP Induction
About the Assay Sygnature Discovery’s CYP Induction assay provides a robust in vitro platform for…
Technical Notes
CYP Inhibition
About the Assay The CYP Inhibition assay evaluates reversible inhibition of seven major human CYP450…
Technical Notes
CYP Inhibition | IC50 Shift
About the Assay The IC50 Shift assay is designed to identify and characterise time‑dependent inhibition…
Technical Notes
CYP Inhibition | Kinact/KI
About the Assay The CYP3A4 (Midazolam) kinact/KI assay is designed to quantify the time-dependent inhibition…
Technical Notes
CYP Reaction Phenotyping
About the Assay The CYP450 Reaction Phenotyping (RePh) assay determines which human CYP450 isoforms are…
Blog
From In Silico to In Vivo: Keeping AI honest in drug development
AI is undeniably transforming drug discovery: from pinpointing promising disease targets to sketching drug-like molecules,…
Case Studies
STORM Therapeutics: From Lead to Pre-Candidate Nomination in 18 Months
Accelerating a best in class DHX9 inhibitor ahead of industry timelines.
Pages
Cookie Policy
News
Bringing Connected Drug Discovery Together Under One Name
For more than 20 years, Sygnature Discovery has partnered with biotech and pharmaceutical companies to…
Pages
Testing Translation
Blog
Building a Biophysical Toolbox: Looking Beyond a “One Size Fits All” Approach to Drug Discovery
Biophysics in Drug Discovery We believe that biophysics plays a key role throughout the drug…
Case Studies
Optimizing Recombinant Cereblon-Midi Expression in E. coli Through Smart Strain Choice
In this article we discuss our workflow for selecting the optimum E. coli strain for…
Case Studies
Recombinant β-catenin (CTNNB1) expression and purification provides an early handle for therapeutic targeting of the Wnt signalling pathway
β-catenin (CTNNB1) is a multifunctional protein that plays a pivotal role in the canonical Wnt…
Blog
Our Learnings from World ADC London: Designing the Next Generation of Smarter, Safer ADCs
At this year’s World ADC London, Sygnature Discovery hosted a panel discussion exploring a topic…
Blog
Welcoming ExpiCHO-S to our mammalian expression portfolio
The Protein & Structure department at Sygnature Discovery are excited to…
Blog
The Power of Metals in Proteins
In this mini-review Sam Bloor discusses the intriguing and essential role…
Case Studies
More Papain, More Problems
The Challenge Clients sometimes as us to generate Fab and Fc pools from a full-length…
Pages
AACR Poster Registration [Modal]
Pages
Direct-to-Biology
Load More

Support

Can't find what you're looking for?

Can't find what you're looking for? Our team can help — whether you need assistance locating a resource, have a research enquiry, or want media information, get in touch and we'll point you in the right direction.

Get in touch